Abstract
Objective: International guidelines recommend monitoring for weight gain and metabolic disturbance in patients prescribed second generation antipsychotics. We aimed to investigate whether a targeted intervention could improve levels of monitoring in a first episode psychosis clinic.
Method: A pre-intervention audit of both metabolic screening rates and specific monitoring of weight and metabolic indices following the initiation of antipsychotic medication was performed in our first episode psychosis clinic. This was repeated 18 months later, following an intervention that included a number of targeted improvement strategies based on an analysis of barriers and enablers to performing monitoring within the clinic. The intervention included provision of monitoring equipment, interactive educational events, reminders and prompts and embedding processes for monitoring within team structure.
Results: There were significant improvements in both the screening of metabolic indices and the monitoring of indices following initiation of antipsychotic medications. There were also improvements in the number of active interventions offered to clients by clinicians. However, the level of guideline concordant monitoring remains low within our service.
Conclusions: A comprehensive programme of implementation strategies can improve both screening and monitoring of the metabolic side-effects of antipsychotic medications. Further focused strategies are necessary to continue to improve monitoring to guideline concordant levels.
Acknowledgments
The authors would like to thank all the clinicians from the service who participated in the quality improvement programme, especially Wei Soong, Karen O'Connor, Yang Yun and Cameron Duff. We would also like to thank Kurt Zhao and Sandy Carmichael for their input into data collection.
Declaration of interest: The study was partly funded by a Melbourne University Knowledge Transfer Grant. Orygen Youth Health receives funds from the Colonial Foundation. Sarah Hetrick is funded via a National Health and Medical Research Council training fellowship. Andrew Thompson has investigator-initiated grants with AstraZeneca and Janssen-Cilag. He has also been awarded a Pfizer Neurosciences Research grant. Patrick McGorry has investigator-initiated grants with AstraZeneca and Janssen Cilag. He has also received honoraria from AstraZeneca, Janssen-Cilag, Pfizer and Eli Lilly. The authors alone are responsible for the content and writing of the paper.